跳至主要内容
临床试验/EUCTR2014-002519-40-AT
EUCTR2014-002519-40-AT进行中(未招募)1 期

A prospective, randomised, non-inferiority study of Chloroprocaine 2% and the active control Ropivacaine 0.75% (AstraZeneca) in ultrasound-guided axillary nerve block for short-duration distal upper limb surgery - Chloroprocaine 2% - Axillary block

Sintetica S.A.0 个研究点目标入组 211 人开始时间: 2015年7月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
211

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Sex and surgery: male and female patients scheduled for short duration (< 60 min) distal upper limb surgery under axillary nerve block anaesthesia
  • 2. Age: = 18 years old
  • 3. Body Mass Index (BMI): 18 - 32 kg/m2 inclusive
  • 4. ASA physical status: I-III
  • 5. Informed consent: signed written informed consent before inclusion in the study
  • 6. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 150
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 61

排除标准

  • 1. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study. Contraindications to peripheral nerve block anaesthesia. History of neuromuscular diseases to the upper extremities
  • 2. Axillary status: Axillary local infections, surgical scarring and pathological lymph node enlargement
  • 3. ASA physical status: IV-V
  • 4. Further anaesthesia: Patients anticipated to be requiring further anaesthesia (general or local anaesthesia)
  • 5. Chronic pain syndromes: Patients with chronic pain syndromes (taking opioids, antidepressants, anticonvulsant agents)
  • 6. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations ingredients; ascertained or presumptive hypersensitivity to the amide and ester-type anaesthetics
  • 7. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study; ascertained psychiatric diseases, sepsis, blood coagulation disorders, insulin dependent diabetes mellitus, terminal kidney failure
  • 8. Medications: Medication known to interfere with the extent of regional blocks (see chloroprocaine and ropivacaine SmPCs) for 2 weeks before the start of the study. Hormonal contraceptives for females will be allowed
  • 9. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study, calculated from the first day of the month following the last visit of the previous study
  • 10. Drug, alcohol: history of drug or alcohol abuse
  • 11. Pregnancy: missing or positive pregnancy test at screening, pregnant or lactating women

研究者

相似试验